Clinical Trial Update: BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for BAY 59-8862 in treating patients with non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• BAY 59-8862

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED